T he satiety agent sibutramine acts in part through a primary amine metabolite, M2. To investigate whether M2 could affect glycaemia independently of satiety and weight loss, groups of normal mice received a single dose of M2 (1 or 10 mg/kg) and food was withheld. Compared with controls (who received vehicle only), M2 (10 mg/kg) decreased basal plasma glucose concentrations, with a maximal decrease of about 25% at 4-8 hours (p<0.05). Soleus muscles were isolated from the mice at intervals: insulin-mediated glucose uptake by the muscles from controls progressively decreased over 24 hours whereas uptake was maintained by muscles from M2-treated mice. Hepatic gluconeogenesis was reduced about 40% by liver snips isolated from M2-treated mice after 24 hours (p<0.05).
Introduction
Sibutramine promotes weight loss by inducing satiety through inhibition of serotonin and noradrenaline reuptake. 1, 2 Sibutramine also stimulates thermogenesis 3 and enhances insulin sensitivity. 4, 5 These effects are associated with improved glycaemic control in type 2 diabetes. 6, 7 Most effects of sibutramine are mediated via its secondary amine M1 and primary amine M2 metabolites. 8 Although weight loss is expected to increase insulin sensitivity, 9 the M2 metabolite has been shown to act directly on cultured muscle cells to increase insulin-mediated glucose uptake. 10 This study in normal mice examines whether the sibutramine metabolite M2 can reduce plasma glucose concentrations, and whether this is associated with increased insulin-mediated glucose uptake into skeletal muscle and/or reduced hepatic glucose output. Mice were treated with M2: then, soleus muscles were isolated at intervals up to 24 hours for determination of glucose uptake by the nonmetabolised analogue 2-deoxy-D-glucose (2DG). Livers were removed at 24 hours to determine glucose output in the presence of lactate and pyruvate.
Material and methods
Homozygous lean +/+ mice from the Aston colony were housed and maintained, as described previously, with food and water available ad libitum except during experimentation. 11 All procedures were carried out in accordance with the UK Home Office Scientific Procedures Act, 1986. Groups of 5-6 mice were used when they were about 20 weeks old and weighed about 35-45 g. Fed mice received either M2 (1 or 10 mg/kg) in 0.9% sodium chloride methyl cellulose mix or vehicle only (control), given by oral gavage. Food was then withheld and mice were killed by cervical dislocation at intervals up to 24 hours. Blood samples for plasma glucose assay 12 were taken from the tail vein. Soleus muscles and hemidiaphragms were removed and 2DG uptake was measured, as previously described. 11 Briefly, isolated muscles were washed, blotted, weighed and preincubated for 10 minutes at 30°C in Krebs-Ringer bicarbonate (KRB) buffer containing 1 mM pyruvate, 0.01% bovine serum albumin (BSA, fraction V) and gassed with 95% O 2 :5% CO 2 . Muscles were then transferred to 1 ml of the same buffer supplemented with 0.1 mM 2DG, 1 µCi/ml 2-deoxy-D-[ 3 H]-glucose and 0.01 µ Ci/ml L-[1-14 C]-glucose. Bovine insulin (10 -8 M) was added and tissue was incubated for 30 minutes at 30°C, then washed in ice-cold KRB buffer and digested in 0.5 ml 1M NaOH. Radioactivity was counted in 5 ml Hi-Safe III scintillant using a Packard 1900TR counter. Tissue uptake of [ 3 H]-2DG was corrected for the extracellular compartment L-[ 14 C]-glucose) and expressed as nmol glucose/mg tissue/30 min.
Hepatic glucose production was assessed 24 hours after 
Results
Administration of M2 (1 or 10 mg/kg) to normal mice reduced basal plasma glucose concentrations compared with control (figure 1). Analysis of variance showed a significant effect of M2 treatment (p<0.05). The effect was dose-related and maximal at 4-8 hours (a reduction of about 25% was observed with the 10 mg/kg dose), although mean plasma glucose concentrations remained lower in the M2-treated groups at 24 hours.
Insulin-mediated glucose uptake was assessed by 2DG uptake with 10 -8 M added insulin, using soleus muscles isolated from mice treated with the higher dose (10 mg/kg) of M2. Glucose uptake declined by about 50% in control mice during the 24-hour period of fasting, whereas mice treated with M2 maintained glucose uptake into soleus muscles (figure 2). Similar data were obtained for glucose uptake by hemidiaphragms (table 1) .
Hepatic gluconeogenesis was assessed using liver snips isolated from mice treated 24 hours previously with the higher dose (10 mg/kg) of M2. M2 reduced glucose production more than 40% compared with control (51.4+4.5 vs. 28.7+2.2 mmol/g/h, n=10, for control and M2-treated groups respectively, p<0.01).
Discussion
The present study demonstrates that the primary amine metabolite M2 of sibutramine can reduce basal plasma glucose concentrations in normal mice. This study provides preliminary data showing that the reduced glycaemia is associated with increased insulin-mediated glucose uptake by skeletal muscle. Additionally, M2 reduced hepatic glucose output after 24 hours and this effect may also have contributed to the reduced glycaemia observed.
Since the effects of M2 were observed during a period when food was withheld, the action of M2 must be independent of its effect to induce weight loss. 2, 8 Whereas insulin-mediated glucose uptake by muscle decreased during fasting, as generally observed in other studies, 14, 15 M2 maintained glucose uptake. This could be explained by increased energy demand that is generated through increased thermogenesis, 3, 16 particularly during initiation of sibutramine therapy. Increased insulin-mediated glucose uptake into skeletal muscle observed after M2 administration in vivo is consistent with studies in L6 muscle cells that have shown a direct stimulatory effect of M2 on insulinmediated glucose uptake by these cells. 10 The effect was ORIGINAL ARTICLE VOLUME 3 ISSUE 3 . DECEMBER 2006 independent of serotonin and noradrenaline reuptake blockade, and occurred during inhibition of phosphatidylinositol 3-kinase, suggesting that the effect is not mediated through the insulin receptor or early post-receptor signals. 10 An increased action of insulin on glucose uptake after M2 administration is consonant with many clinical studies showing that sibutramine improves glycaemic control without stimulation of insulin secretion in overweight and obese patients with type 2 diabetes. 6, 7, [17] [18] [19] [20] The present study suggests that M2 has an acute effect (within 24 hours), increasing insulin-mediated glucose uptake. The present study also indicates that the effect is independent of weight reduction during chronic sibutramine administration, although concomitant weight reduction is likely to facilitate improved insulin sensitivity further. 5, 9 Hepatic glucose production after a 24-hour fast, and in the presence of 10 mM lactate and 1 mM pyruvate, will largely reflect gluconeogenesis. 21 Suppression of hepatic gluconeogenesis after M2 administration in the present study raises the possibility that such an effect contributes to the weight-independent and satiety-independent glucose-lowering effect of sibutramine. However, the present design does not indicate whether this is related to increased hepatic insulin sensitivity.
In conclusion, this study provides preliminary evidence that the primary amine metabolite M2 of sibutramine can reduce glycaemia, increase insulin-mediated glucose uptake by skeletal muscle and reduce hepatic glucose output in normal lean mice.
